Check each claim against its experiments, reported results, scope, and stated limitations.Know what the science actually supports before you trust the answer.
Press Enter β΅ to start review
Explore by Goal
"The scientific man does not aim at an immediate result. He does not expect that his advanced ideas will be readily taken up. His work is like that of the planter - for the future. His duty is to lay the foundation for those who are to come, and point the way."
- Nikola Tesla
Quick Explanation
Copied
Paper in one breath
Steroid-naΓ―ve AIH is associated with reduced gut microbial diversity, a distinct taxonomic composition, and a strong enrichment of Veillonella (especially V. dispar) that correlates with liver inflammation markers (AST), plus functional dysbiosis inferred from 16S data; the authors propose a 4-genus stool signature that discriminates AIH vs controls with AUROC ~0.78 (discovery) and ~0.81 (validation).
Long Explanation
BGPT Rigorous Paper Review (science-focused)
Topic: Alterations of gut microbiome in autoimmune hepatitis (Gut; online published 14 June 2019).
1) VISUAL: Study design map (what was compared and when)
Evidence: steroid-naΓ―ve sampling prior to corticosteroids; discovery/validation split done prior to analysis; sample collection and processing described.
2) VISUAL: Diagnostic performance (AUROC) of the proposed microbiome signature
Evidence: Veillonella AUROC ~0.70 (exploration) and ~0.69 (validation); 4-genus signature AUROC ~0.78 (exploration) and ~0.81 (validation); models based on 11 genera not improving materially.
3) VISUAL: Direction of association for key taxa
Evidence: increased genera include Veillonella, Klebsiella, Streptococcus, Lactobacillus, while decreased genera include Clostridiales, RF39, Ruminococcaceae, Rikenellaceae, Oscillospira, Parabacteroides, Coprococcus; Veillonella most strongly associated with AIH status, driven by V. dispar.
4) VISUAL: Microbeβinflammation link reported for V. dispar (AST)
Evidence: partial Spearman correlations (adjusted) show Veillonella vs AST rho=0.216 (p=0.022) and V. dispar vs AST rho=0.266 (p=0.005); dichotomizing by median V. dispar abundance shows higher AST with p=0.010.
Evidence: LEfSe found 32 KEGG categories differentially abundant and MaAsLin found 17 significant functional modules after covariate adjustment; reported themes include enriched LPS biosynthesis, increased tryptophan metabolism and lysine degradation, depleted arginine/proline metabolism, enriched glutathione metabolism, and decreased bacterial chemotaxis/motility.
6) EXPLAIN: What is actually known vs inferred (and what is uncertain)
Known from this paper (directly measured / computed)
Alpha diversity is lower in steroid-naΓ―ve AIH vs matched controls (Shannon and observed OTUs reported with p-values).
Beta diversity differs between AIH and controls by unweighted UniFrac (pseudo-F 3.31, p=0.002) and other distance metrics.
Taxa enrichment/depletion is reported, including strong disease association for Veillonella dispar (p=8.85e-8) and correlated direction with AST.
Predictive discrimination: a 4-genus logistic regression model discriminates AIH vs controls with AUROC ~0.78 (exploration) and ~0.81 (validation).
Inferred in this paper (prediction, not direct assay)
Functional dysbiosis is inferred from 16S using PICRUSt (metagenome prediction from marker gene profiles).
Thus, statements like βLPS biosynthesis is over-representedβ are model-based and require metagenomics/metatranscriptomics or direct metabolite measurements to become mechanistically firm. (This is a methodological limitation consistent with the general premise of marker-gene functional prediction.)
This is explicitly an association study (cross-sectional). Even if V. dispar tracks AST and inflammation grade, that does not establish that it drives disease rather than reflecting the gut environment altered by disease or treatment context.
The paper uses 16S rRNA sequencing; that limits species-level discrimination and constrains function to predictions rather than direct enzymatic/metabolite evidence. The authors state this as a limitation.
7.3 Confounding by medications & sampling context
The study adjusts for antibiotic and UDCA exposure, but treats covariates dichotomously (no dose modeling), and other medication categories (e.g., proton pump inhibitors) are not accounted for. This can create residual confounding, especially in microbiome studies where multiple exposures can shift communities.
7.4 Generalizability across regions
The microbiome has strong geographic/host-context variability; the authors cite work indicating reference-range limitations due to regional variation. This threatens transferability of any stool βsignatureβ model trained in one centre/population.
7.5 Overfitting risk in biomarker modeling (small validation)
Even with a prior discovery/validation split, the validation cohort is modest (AIH n=28; controls n=34). AUROC stability depends on sample size; a robust clinical-grade model needs repeated external validation and calibration assessment beyond AUROC. The paper reports AUROC and CIs, but does not (in the provided full text) show calibration plots or decision-curve analysis.
8) Where this fits mechanistically (only what is supported)
The paper proposes a plausible gutβliver axis: microbial dysbiosis may influence immune activation and hepatic inflammation. This is consistent with broader gutβliver axis framing in the microbiome literature.
Specifically, the paper links Veillonella enrichment with predicted LPS biosynthesis and argues alignment with inflammatory cytokines in AIH contexts, but the current evidence is not direct causal mechanistic proof in AIH patients.
Most defensible claim: This paper provides evidence that steroid-naΓ―ve AIH gut microbiota differs from matched controls in diversity and composition, with a strong Veillonella/V. dispar signal, and that these microbiome features can discriminate AIH vs controls with moderate-to-good AUROC in the reported cohorts.
Less defensible / uncertain: The functional pathway claims (e.g., βLPS biosynthesis over-representedβ) are prediction-based from 16S and require direct multi-omics or metabolite assays for higher confidence.
10) Author-review buttons (bespoke deeper dives on each authorβs work)
Feedback:
Updated: April 15, 2026
BGPT Paper Review
Study Novelty
70%
Moderately novel: a relatively large, steroid-naΓ―ve AIH cohort with an internal discovery/validation split supports a specific stool-based signature centered on Veillonella/V. dispar, and the study adds functional-prediction themes; however, gutβliver axis microbiome associations and biomarker modeling are established approaches in the broader literature.
Scientific Quality
60%
Scientific quality is solid for observational microbiome biomarker work (matched cohorts, explicit validation cohort, covariate adjustment, multiple diversity metrics), but limited by 16S-only resolution, PICRUSt-based functional inference, potential residual confounding from medications/diet/environment, modest validation sample size for model generalizability, and lack of direct functional/metabolite verification.
Study Generality
60%
Findings are reasonably specific to steroid-naΓ―ve AIH in the studied setting and may not generalize across geography, diet, and unmeasured medications; regional variability in reference/disease microbiome models is a known concern.
Study Usefulness
80%
High practical utility as a hypothesis-generating and biomarker-discovery piece: it provides a concrete stool signature (Veillonella/Lactobacillus/Oscillospira/Clostridiales) with reported AUROC and links Veillonella/V. dispar to AST, enabling targeted external validation and mechanistic follow-up.
Study Reproducibility
60%
Methods are described (QIAamp stool DNA kit, MiSeq, QIIME2 v2018.2, DADA2, vsearch OTU clustering at 97%, rarefaction to 20,178 reads, PICRUSt, LEfSe, MaAsLin, logistic regression, ROC/AUC), but the provided text does not establish public access to raw sequencing data or full code, and functional inference adds additional reproducibility complexity.
Explanatory Depth
70%
The paper provides an explanatory narrative connecting Veillonella enrichment and inferred LPS biosynthesis to inflammation and maps multiple predicted amino-acid metabolism modules, but mechanistic claims remain speculative due to 16S-only and PICRUSt-based functional prediction, and the study remains cross-sectional.
It computes and visualizes AUROC and taxon-direction summaries from the paperβs reported values, then generates a concise model-feature table for cross-cohort replication planning.
Get emailed when your analysis is done!
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
βV. dispar is a primary driver of AIH severity in humans.β This is less supported because the study is cross-sectional with predicted functional changes from 16S and lacks direct causal manipulation in AIH patients.
βFunctional module differences prove altered LPS signaling mechanisms.β Less favored because functional conclusions are inferred from marker genes using PICRUSt, which can misestimate pathway abundance.
Explore by Goal
Quick Explanation
Long Explanation
Top Data Sources
Ask a Follow-Up
Key Insight
Keep Exploring
Analysis 
Hypothesis Graveyard
Potential Experiments
Discussion